Story
Intuitive Surgical Upgraded by Oppenheimer on Strategy to 'Crowd Out' U.S. Rivals

Oppenheimer has upgraded its rating on Intuitive Surgical (NASDAQ: ISRG) to Outperform from Perform, establishing a new price target of $500 per share. The investment firm's note on Wednesday cited the robotic surgery leader's effective strategy of "crowding out" domestic competition as a key driver for its more bullish stance.
Analyst's Thesis: Sidelining Competitors
Analyst Suraj Kalia stated the upgrade reflects "a more nuanced risk-reward assessment at these levels," according to the note. Oppenheimer's central argument is that Intuitive's business tactics, including its use of operating leases and customized price-volume contracts, make it financially punitive for U.S. rivals to gain market share.
The firm also highlighted that Intuitive's per-click business model provides significant flexibility, aiding its penetration into more price-sensitive, lower-acuity settings like Ambulatory Surgery Centers (ASCs).
U.S. Competitive Landscape
Oppenheimer characterized U.S. competition as a "non-factor" for Intuitive Surgical at present. The firm's field checks reportedly uncovered significant operational and logistical hurdles for competing systems.
Ad- Johnson & Johnson's Ottava: Oppenheimer's checks flagged "unique workflow challenges" for the Ottava platform, specifically related to arm deployment in a non-sterile environment. The note also pointed to limited production capacity, projecting just 20 systems in 2026 and 100 in 2027.
- Hugo System: The competing platform from Medtronic was said to face "real-estate issues," limiting its appeal.
International Headwinds and Market Growth
While confident in Intuitive's domestic dominance, the note was more cautious about the international landscape, where the company generates about 34% of its sales. Oppenheimer identified homegrown Chinese platforms—specifically Medbot, Kangduo, and Toumai—as "the biggest threats from a pricing/market share perspective."
Looking at the broader market, Oppenheimer forecasts the total robotic surgery market will grow to approximately 5.5 million procedures by 2030. This expanding market provides a significant backdrop for the ongoing competitive dynamics in the sector.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.